Nomination period for the Broermann Medical Innovation Award started

17.1.2025 12:17:33 CET | news aktuell GmbH | Press release

Share

Prize money of one million euros higher than the prize money for the Nobel Prize for Medicine
Award honors researchers worldwide who have done pioneering work in medicine, biotechnology, or related fields

Gießen, January 17, 2025. The nomination period for the Broermann Medical Innovation Award has started. The prize, which will be awarded for the first time this year, is aimed at scientists worldwide who have carried out pioneering work in medicine, biotechnology, or related fields with their research.
The nomination portal (www.broermann-award.org/nomination/) is open until March 1, 2025. At one million euros, the prize is more valuable than the Nobel Prize for Medicine, making it one of the most highly endowed awards for medical research worldwide.

The international Broermann Medical Innovation Award recognizes research results that demonstrate a high level of innovation for clinical application and thus have the potential to improve the lives and health of millions of people worldwide. The prize is aimed at scientists whose research has been pioneering in the fields of medicine, biotechnology, or related sciences.

The Broermann Medical Innovation Award was established in 2024 to honor the vision and commitment of Dr. Bernard große Broermann, the founder of the Asklepios Kliniken. The Broermann gemeinnützige GmbH sponsors the award, and the University Hospital Giessen and Marburg (UKGM) manages the organization. “With this award, we want to honor groundbreaking medical discoveries and highlight those whose research brings real improvements in the prevention or treatment of diseases,” says Prof. Werner Seeger, Chairman of the Award Committee. For the Medical Director of the UKGM, Prof. Friedrich Grimminger, the unique prize reflects the clear conviction of the company founder: “Scientific excellence in medicine is always an international team effort, but without the genius of individual researchers, networks are limited in their impact. These key players and drivers of medical innovation should be promoted and recognized worldwide.”

Nomination process and deadlines
Nominations for the Broermann Medical Innovation Award can be submitted until March 1, 2025. The incumbent Hessian Minister President will present the award in December 2025 at the Hessian State Chancellery in Wiesbaden.

Further information on the award, the nomination criteria, and the selection process can be found at www.broermann-award.org

For further information, please contact

Broermann Medical Innovation Award
Mirjam Malko
Tel.: +49 (0) 641 / 985-42310
E-Mail: contact@broermann-award.org


Asklepios Kliniken
Corporate Communications and Marketing
Tel.: + 49 (0) 40 / 18 18-82 66 36 
E-Mail: presse@asklepios.com
24-hour on-call service for the press office: +49 (0) 40 / 1818-82 8888

Visit Asklepios on the Internet, Facebook or YouTube:
www.asklepios.com
www.asklepios.com/konzern/gesundheitsmagazin 
www.facebook.com/asklepioskliniken
www.youtube.com/asklepioskliniken 

RHÖN-KLINIKUM AG
Corporate Communications and Marketing
Heike Ochmann
Press Spokeswoman
Tel.: +49 (0) 9771 / 65-12130 
E-Mail: heike.ochmann@rhoen-klinikum-ag.com  

MEDICLIN AG
Dr. Janina Lossen
Press Spokeswoman
Tel:. +49 (0) 781 / 488-180
E-Mail: presse@mediclin.de

UKGM
Frank Steibli
Head of Communications and Press Spokesman 
Tel.: +49 (0) 641 / 985-51020
Mobile: +49 (0) 160 / 7120456
E-Mail: frank.steibli@uk-gm.de 

Subscribe to releases from news aktuell GmbH

Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from news aktuell GmbH

Grünenthal strengthens its Genetic Medicine Capabilities and joins the Cluster for Nucleic Acid Therapeutics Munich16.7.2026 10:42:31 CEST | Press release

Aachen, Germany, 16 July 2026 – Grünenthal announced today that the company has joined the Cluster for Nucleic Acid Therapeutics Munich (CNATM), a Munich-centred innovation network that brings together leading universities, research institutions, biotech companies and industry partners to accelerate next-generation nucleic acid therapeutics into innovative treatments that can make a meaningful difference for patients

Acrobat Studio og Acrobat KI-assistent: den nye generasjonen KI-støttet produktivitet – nå også på norsk8.7.2026 15:08:48 CEST | Press release

SAN JOSE, Calif. - 8. juli 2026 - Adobe utvider tilgjengeligheten til Acrobat Studio og Acrobat KI-assistenten i Norge. Nå er de KI-støttede funksjonene for produktivitet og kreavtivitet også tilgjengelige på norsk, og kan dermed brukes av brukere på lokalt språk. Acrobat Studio kombinerer Adobe Acrobat Pro, Adobe Express Premium og smarte KI-assistenter. Acrobat KI-assistent er også tilgjengelig som et separat tillegg for alle Adobe Acrobat-produkter (Acrobat Reader, Acrobat Standard og Acrobat Pro) – et fleksibelt alternativ for alle som ønsker å bruke KI-støttede funksjoner kun når de arbeider med dokumenter. Begge disse tilbudene gjør det mulig for brukere å raskere samle inn informasjon i PDF-er og Office-dokumenter, opprette innhold og effektivisere arbeidsflyten. Acrobat Studio og Acrobat KI-assistenten markerer et viktig trinn i utviklingen av PDF-filen, som har blitt standarden for viktige dokumenter siden den ble lansert av Adobe i 1993. Acrobat utvikler seg fra et ledende pr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye